GlobeNewswire
-
Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
26/10/2026 -
BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH’s RECOVER-TLC Third Annual Workshop
26/10/2026 -
Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
26/10/2026 -
Affordable Pet Labs Launches Nationwide Validation Study of an At-Home Heartworm Test, and Invites Dog Owners in 52 Cities to Help
26/10/2026 -
Amwell® to report third quarter 2026 operating results
26/10/2026 -
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
26/10/2026 -
Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
26/10/2026 -
Artelo Biosciences to Showcase First-in-Human FABP5 Inhibitor ART26.12 as a Novel Approach to Pain Treatment at IASP 2026 World Congress on Pain
26/10/2026 -
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
26/10/2026 -
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
26/10/2026 -
Transactions under Novonesis’ share buyback program
26/10/2026 -
U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week
26/10/2026 -
NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries
26/10/2026 -
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26/10/2026 -
X9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical Study
26/10/2026 -
Major shareholder announcement
26/10/2026 -
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
26/10/2026 -
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
26/10/2026 -
More Than 1 in 10 People Receive Medically Actionable Genetic Results Through 23andMe, Analysis of Nearly 6 Million Participants Finds
26/10/2026
Pages